个性化文献订阅>文章检索

文章名     作者     期刊名     摘要     卷     期         如果没有找到您所需要的文献，请点击 ——此处申请     共9条记录   PLINABULIN Tubulin Polymerization Inhibitor Vascular-Disrupting Agent Oncolytic [作者：Ferrer, E; Bolos, J; Castaner, R,期刊：Drugs of the Future, 页码：11-15 , 文章类型： Article，,卷期：2010年35-1] Vascular-disrupting agents (VDAs) are a new class of compounds that target tumor vasculature, causing a rapid and acute collapse of the blood vessel network surrounding the tumor, slowing blood flow and ultimately result... BIBF 1120 Angiogenesis Inhibitor Oncolytic [作者：Hilberg, F; Roth, GJ; Merger, M; Kaiser, R,期刊：Drugs of the Future, 页码：5-10 , 文章类型： Article，,卷期：2010年35-1] Angiogenesis, the formation of new blood vessels from pre-existing vasculature, is a fundamental process for tumor growth and metastasis. BIBF 1120 (planned brand name Vargatef (TM)) is a novel, oral, potent angiokinase ... VOLOCIXIMAB Anti-alpha(5)beta(1) Integrin Monoclonal Antibody Angiogenesis Inhibitor Oncolytic [作者：Tamaskar, I,期刊：Drugs of the Future, 页码：16-20 , 文章类型： Article，,卷期：2010年35-1] Integrins are dimeric proteins expressed on the surface of most cells in the body. Their primary function is to maintain a dynamic adhesion between the cell and its microenvironment. These transmembrane receptors bind ex... EP3 RECEPTOR ANTAGONISTS: POTENTIAL FOR IMPROVING SAFETY IN THE ANTIPLATELET THERAPY FIELD [作者：Singh, J; Kiselyov, AS,期刊：Drugs of the Future, 页码：21-31 , 文章类型： Review，,卷期：2010年35-1] Current antiplatelet therapies offer significant benefits for the treatment of patients at risk for recurrent cardiovascular events. However, clinical data suggest that many of these agents lead to an increased risk of s... HIGH-DENSITY LIPOPROTEIN MODULATION TARGETS [作者：Mousa, SS; Block, RC; Mousa, SA,期刊：Drugs of the Future, 页码：33-39 , 文章类型： Review，,卷期：2010年35-1] Given the strong genetic determinants of favorable high-density lipoprotein cholesterol (HDL-C) levels, the ability to achieve the cardiovascular and longevity benefits associated with this mediator of the reverse choles... THERAPEUTIC STRATEGIES IN CACHEXIA: CURRENT AND FUTURE DIRECTIONS [作者：Argiles, JM; Sirisi, S; Lopez-Soriano, FJ; Busquets, S,期刊：Drugs of the Future, 页码：41-52 , 文章类型： Review，,卷期：2010年35-1] Cachexia is a complex syndrome. The main components of this pathological state are anorexia and metabolic abnormalities, such as glucose intolerance, fat depletion and muscle protein catabolism. The aim of the present ar... APPROACHES TO ASSESSING DRUG SAFETY IN THE DISCOVERY PHASE HIGHLIGHTS OF THE SOCIETY FOR MEDICINES RESEARCH SYMPOSIUM HELD ON SEPTEMBER 24TH, 2009, AT THE NATIONAL HEART & LUNG INSTITUTE, KENSINGTON, LONDON, UK [作者：Allen, J; Jeffrey, P; Williams, R; Ratcliffe, AJ,期刊：Drugs of the Future, 页码：67-75 , 文章类型： Article，,卷期：2010年35-1] The Society for Medicines Research symposium, sponsored by Apredica, Cwathmey Preclinical Services, Gentronix and Cyprotex, was held at the National Heart and Lung Institute, Kensington, London, U.K. The meeting, organiz... NEW THERAPEUTIC APPROACHES FOR WALDENSTROM'S MACROGLOBULINEMIA [作者：Stedman, J; Roccara, A; Leleu, X; Ghobrial, IM,期刊：Drugs of the Future, 页码：53-58 , 文章类型： Article，,卷期：2010年35-1] Waldenstrom's macro globulinemia (WM) is a B-cell disorder characterized by the infiltration of the bone marrow with lymphoplasmacytic cells, as well as detection of an immuno globulin M (IgM) monoclonal gammopathy in th... AN OVERVIEW ON THE CYCLIN-DEPEN DENT KINASE 9-RELATED PATHWAY [作者：Romano, G,期刊：Drugs of the Future, 页码：59-66 , 文章类型： Article，,卷期：2010年35-1] The cyclin-dependent kinase 9 (CDK9)-related pathway is a key factor in the regulation of mammalian cell biology. Its main role consists of regulating transcription via phosphorylation of the RNA polymerase II carboxyl-t...